Promoter holding
64.27%
BL
Bioplus Life Sciences Private Limited - Due diligence report
A 360° intelligence report on Bioplus Life Sciences: trust score, financial health, credit view, compliance, directors, growth and distress …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Bioplus Life Sciences — 360° Intelligence Report
Generated from MCA filings & public records86/100
Trust Score
Low Risk
Bioplus Life Sciences is assessed as Low Risk with a Trust Score of 86/100. Bioplus Life Sciences is an active private limited indian non-government company incorporated in 2004, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 05 Jul 2026 from the latest processed filings. Bioplus Life Sciences Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
86/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
72/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
60/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (A3).
Charges position: 1 open (85.40 cr) · 1 satisfied (20.60 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 1 | 48.0 cr |
| Canara Bank | 1 | 48.0 cr |
Compliance Score: 72/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 3 court forum(s).
- Delayed payments to MSME suppliers disclosed (86 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| NEHA AURORA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUNDEEP AURORA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUNJEEV AURORA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rhea Ishani Aurora | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 4 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
2
Group entities
2
Capital events
1 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Fairbrook Group Limited | Subsidiary Company | 74.00% |
| Bioplus Healthcare Private Limited | Subsidiary Company | 74.00% |
| Vb Medicare Private Limited | Subsidiary Company | 74.00% |
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 60 · Distress 80
Growth signals & trust indicators
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
EPFO headcount growing - hiring signal.
Operating for 22+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 0.86 in a year.
1 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 1.57 cr.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence79/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment89/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 85.40 cr already registered.
- Compliance record supports lending.
Investor view79/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events29 Oct 2025
Director appointed
NEHA AURORA (Additional Director)
Director appointed
Rhea Ishani Aurora (Additional Director)
30 Sep 2025
Director ceased
NEHA AURORA
Last AGM held
Annual general meeting
12 Jun 2025
Charge satisfied
Canara Bank
15 Apr 2025
Charge created
Others - 85.40 cr
31 Mar 2025
Latest balance sheet
Filed with ROC
06 Jun 2016
Securities allotted
321429 Equity Shares - 32.14 cr raised
04 Mar 2016
Director ceased
ASHISH AHLUWALIA
12 Aug 2015
Director ceased
AJAY LAL
05 Dec 2011
Director ceased
KRISHAN KUMAR AURORA
09 May 2011
Director ceased
BARRY CLARE
29 Mar 2010
Director ceased
RAJEEV KALRA
23 Sep 2009
Director ceased
SUNEET AURORA
Director ceased
SUNJEEV AURORA
10
Key Observations
Auto-generated from the data aboveRevenue declined 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 2 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of A3 from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Novaphene | U99999MH1987PTC044349 | Mumbai, Maharashtra, India |
| Kinjal Organics Private Limited | U24230GJ2019PTC110136 | Ahmedabad, Gujarat, India |
| C & E Limited | U51909WB1961PLC025027 | Kolkata, West Bengal, India |
| Synthokem Labs | U15499TG1994PTC019102 | Patancheru, Telangana, India |
| Retort Chemicals Private Limited | U24100MH1974PTC017171 | Mumbai, Maharashtra, India |
| Abci Agrochem Private Limited | U01100PB2019PTC050131 | Bathinda, Punjab, India |
| Shree Ram Colloids Private Limited | U24133RJ2005PTC020920 | Jodhpur, Rajasthan, India |
| Keva | U24290MH2017PTC292382 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Bioplus Life Sciences before audits and certifications: compliance score 72/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Bioplus Life Sciences: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 60/100, margin trends, ownership structure and peer set for Bioplus Life Sciences - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 86/100, distress signals and MSME payment-delay disclosures - know whether Bioplus Life Sciences pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Bioplus Life Sciences - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Bioplus Life Sciences an active company?
Bioplus Life Sciences has MCA status “Active” with a compliance score of 72/100 (Moderate).
Is Bioplus Life Sciences financially healthy?
Bioplus Life Sciences has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Bioplus Life Sciences?
Its overall Trust Score is 86/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Bioplus Life Sciences?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.
Does Bioplus Life Sciences have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.
Is Bioplus Life Sciences up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 72/100 (Moderate).
Is it risky to lend to Bioplus Life Sciences?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
